A few things on my mind:
A very strange — and painful — year in biotech calls for an unusual nominee to occupy a spot on my annual list of the best CEOs, which is why I’m looking at Catalyst Biosciences’ Nassim Usman.
Usman and the Catalyst board are working to wind down the long-troubled company’s operations and sell off assets. On Wednesday, Catalyst announced that it would be returning approximately $65 million to shareholders. The funds came from the sale of a portfolio of drug candidates to Vertex Pharmaceuticals.
About the Author Reprints
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.